Mesoblast (ASX:MSB) Accumulated Depreciation: A$0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:MSB Mesoblast Ltd ASX:MSB
32 GF Score
Price A$2.23
! 4 Warning Signs
View Full Analysis

What is Mesoblast Accumulated Depreciation?

Mesoblast ASX:MSB 32 Accumulated Depreciation is A$0.00 Mil as of Mar. 2026. GuruFocus rates ASX:MSB with a GF Score™ of 32/100. The stock has 4 warning signs investors should review.

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

Mesoblast's annual accumulated depreciation declined from Jun. 2023 (A$-32.75 Mil) to Jun. 2024 (A$-30.56 Mil) but then stayed the same from Jun. 2024 (A$-30.56 Mil) to Jun. 2025 (A$-27.91 Mil).

Mesoblast Accumulated Depreciation Related Terms

Mesoblast Accumulated Depreciation Historical Data

* Premium members only.

The historical data trend for Mesoblast's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mesoblast Accumulated Depreciation Chart

Mesoblast Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Accumulated Depreciation
Get a 7-Day Free Trial Premium Member Only Premium Member Only -26.07 -32.75 -30.56 -27.91 0.00

Mesoblast Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accumulated Depreciation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -27.91 0.00 0.00 0.00 0.00
ASX:MSB
32GF Score
Mesoblast Ltd ASX:MSB
Accumulated Depreciation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mesoblast Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

What does a Accumulated Depreciation of A$0.00 Mil mean?
Mesoblast (ASX:MSB) has a Accumulated Depreciation of A$0.00 Mil as of Mar. 2026. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Mesoblast and its competitors.
Is Mesoblast's Accumulated Depreciation too high?
Mesoblast's current Accumulated Depreciation is A$0.00 Mil. Overall, Mesoblast has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Mesoblast's Accumulated Depreciation compare to VRTX and REGN?
Mesoblast's Accumulated Depreciation of A$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accumulated Depreciation for a Biotechnology company?
A good Accumulated Depreciation depends on the Biotechnology industry context. However, Accumulated Depreciation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accumulated Depreciation mean?
A high Accumulated Depreciation can signal that a stock is expensive relative to its fundamentals. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Mesoblast and its competitors. Mesoblast's current Accumulated Depreciation is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mesoblast stock overvalued right now?
Mesoblast (ASX:MSB) has a current Accumulated Depreciation of A$0.00 Mil. The current Accumulated Depreciation is A$0.00 Mil. Mesoblast's overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accumulated Depreciation calculated?
Accumulated Depreciation is calculated from a company's financial statements. For Mesoblast (ASX:MSB), the current Accumulated Depreciation is A$0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Mesoblast Business Description

Address 55 Collins Street, Level 38, Melbourne, VIC, AUS, 3000
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
32GF Score

Get the complete analysis for ASX:MSB

Accumulated Depreciation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.23
Price